Highly Compensated Employee (HCE)

Highly Compensated Employee (HCE) in the context of employer-sponsored 401(k) plans refers to an individual who falls under a specific income threshold set by the Internal Revenue Service (IRS). This designation is crucial in administering retirement plans, as it determines the level of contribution limits and compliance testing required to maintain the plan's tax-qualified status.

To be considered an HCE, an employee must meet one of the following criteria:

  • The employee received more than a certain compensation threshold (e.g., $130,000 in a year), adjusting annually for inflation.

  • The employee is a 5% owner of the company at any time during the current or preceding year.

  • The employee belongs to the top-paid 20% of all employees in the company.

 

HCE status can impact the 401(k) plan in several ways. One significant effect is the annual ADP (Actual Deferral Percentage) and ACP (Actual Contribution Percentage) tests. These tests ensure that contributions made by HCEs are not disproportionately higher than those of non-HCEs, avoiding potential discrimination issues.

 

Failure to pass these compliance tests can lead to corrective measures, such as returning excess contributions to HCEs or making additional contributions to non-HCEs. Employers must monitor HCE status and adjust contributions accordingly to maintain the 401(k) plan's tax-favored status and benefits for all employees.

Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.